The short answer
Kava may add to butorphanol-related drowsiness and impairment. The exact combination has not been shown to produce a particular adverse-event rate, but the sedating effects warrant review before co-use.
What this answer covers
Piper methysticum products; beverages and extracts are not interchangeable.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- butorphanol
The medicine itself affects alertness
An intravenous butorphanol study found dose-related sedation and impaired performance. Combining it with midazolam increased these effects, but that prescription sedative is not evidence for the size of a supplement interaction.
What the supplement evidence adds
Supplement guidance cautions about other sedating substances. A kava and valerian trial did not establish sleep or anxiety benefit, but this does not show that combining a preparation with butorphanol is free of impairment.
The exact product and route matter
Butorphanol nasal spray and injected butorphanol have different dosing and exposure. There is no established safe supplement dose or short timing gap for this pair.
Respond to sedation promptly
Discuss the product with the prescriber before use and avoid driving while impaired. Slow or difficult breathing or unusual difficulty waking needs emergency help. Do not adjust butorphanol yourself.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation precaution supported by exact human butorphanol labeling and supplement effects/guidance; midazolam trial is indirect for this supplement, with no transferable incidence.
- Exact scope
- Piper methysticum products; beverages and extracts are not interchangeable. with Butorphanol1841 IN; human nasal tartrate or IV/IM tartrate, with route-specific label distinctions.
- Medication form and route
- intranasal medication; intravenous medication; intramuscular medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed butorphanol
Mixed opioid agonist-antagonist with sedation and respiratory-depression warnings; general serotonergic-drug and CYP3A4 interaction precautions.
How this applies: Exact butorphanol RxCUI 1841 IN, with stated salt/formulation/route bridge.
Nasal formulation-specific pharmacokinetic warnings; not an oral drug or veterinary preparation.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed butorphanol
Warns about CNS-depressant combinations and serotonin syndrome with serotonergic drugs.
How this applies: Exact butorphanol RxCUI 1841 IN, with stated salt/formulation/route bridge.
No exact supplement-pair event rate; nasal CYP3A wording is not assumed identical for injection.
Source 3: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for butorphanol only within the stated preparation and endpoint limits.
Not a direct butorphanol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for butorphanol only within the stated preparation and endpoint limits.
Not a direct butorphanol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 126 healthy preoperative patients.
Dose-related sedation and psychomotor impairment; high-dose combination produced greater-than-additive sedation and respiratory slowing. No significant euphoria or dysphoria.
How this applies: Published abstract is truncated at 250 words; no supplement tested and rates cannot transfer to nasal dosing or botanical combinations.
Published abstract is truncated at 250 words; no supplement tested and rates cannot transfer to nasal dosing or botanical combinations.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact butorphanol article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 293a5a38bb41fe18
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.